Metformin in cancer treatment and prevention

Annual Review of Medicine

Volumn 66, Issue , 2015, Pages 17-29

  Morales, Daniel R ^a   Morris, Andrew D ^b  

^a Medical Education Institute   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

clinical trials; diabetes; epidemiology; oncology

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PREVENTION; CANCER THERAPY; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DRUG MECHANISM; ENDOMETRIUM CANCER; ESOPHAGEAL ADENOCARCINOMA; HUMAN; LIVER CANCER; NON INSULIN DEPENDENT DIABETES MELLITUS; NON SMALL CELL LUNG CANCER; OBSERVATIONAL STUDY; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; RISK REDUCTION; DIABETES MELLITUS, TYPE 2; NEOPLASMS;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASMS;

EID: 84921405225     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-062613-093128     Document Type: Article

References (72)

1. Wild S, Roglic G, Green A, et al. 2004. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-53
2. American Diabetes Association. 2013. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 36:1033-46
3. Saltiel AR, Kahn CR. 2001. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414:799-806
4. Spellman CW. 2010. Pathophysiology of type 2 diabetes: targeting islet cell dysfunction. J. Am. Osteopath. Assoc. 110:S2-7
5. Vigneri P, Frasca F, Sciacca L, et al. 2009. Diabetes and cancer. Endocr. Relat. Cancer 16:1103-23
6. Barone BB, Yeh HC, Snyder CF, et al. 2008. Long-Term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-Analysis. JAMA 300:2754-64
7. De Bruijn KM, Arends LR, Hansen BE, et al. 2013. Systematic review and meta-Analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br. J. Surg. 100:1421-29
8. Bensimon L, Yin H, Suissa S, et al. 2014. Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes Control 25:329-38
9. Ma J, Li H, Giovannucci E, et al. 2008. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-Term survival analysis. Lancet Oncol. 9:1039-47
10. Giovannucci E, Harlan DM, Archer MC, et al. 2010. Diabetes and cancer: a consensus report. Diabetes Care 33:1674-85
11. Frasca F, Pandini G, Sciacca L, et al. 2008. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch. Physiol. Biochem. 114:23-37
12. Sachdev D, Yee D. 2007. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol. Cancer Ther. 6:1-12
13. Nestler JE, Powers LP, Matt DW, et al. 1991. A direct effect of hyperinsulinemia on serum sex hormonebinding globulin levels in obese women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 72:83-89
14. Key T, Appleby P, Barnes I, Reeves G. 2002. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl. Cancer Inst. 94:606-16
15. Gonda TA, Tu S, Wang TC. 2009. Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle 8:2005-13
16. NathanDM, Buse JB, Davidson MB, et al. 2009. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193-203
17. Viollet B, Guigas B, Sanz Garcia N, et al. 2012. Cellular and molecular mechanisms of metformin: an overview. Clin. Sci. 122:253-70
18. El-Mir MY, Nogueira V, Fontaine E, et al. 2000. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 275:223-28
19. Viollet B, Guigas B, Leclerc J, et al. 2009. AMP-Activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol. 196:81-98
20. VanderHeidenMG, CantleyLC, Thompson CB. 2009. Understanding the Warburg effect: themetabolic requirements of cell proliferation. Science 324:1029-33
21. Levine AJ, Puzio-Kuter AM. 2010. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330:1340-44
22. Faubert B, Boily G, Izreig S, et al. 2013.AMPKis a negative regulator of theWarburg effect and suppresses tumor growth in vivo. Cell Metab. 17:113-24
23. WuSB, Wei YH. 2012. AMPK-mediated increase of glycolysis as an adaptive response to oxidative stress in human cells: implication of the cell survival in mitochondrial diseases. Biochim. Biophys. Acta 1822:233-47
24. Mehenni H, Gehrig C, Nezu J, et al. 1998. Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity. Am. J. Hum. Genet. 63:1641-50
25. KalaanyNY, Sabatini DM. 2009. Tumours with PI3K activation are resistant to dietary restriction. Nature 458:725-31
26. Vander Heiden MG, Plas DR, Rathmell JC, et al. 2001. Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol. Cell. Biol. 21:5899-912
27. Shackelford DB, Abt E, Gerken L, et al. 2013. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 23:143-58
28. Vazquez-Martin A, Colomer R, Brunet J, et al. 2008. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif. 41:59-85
29. Xiang X, Saha AK, Wen R, et al. 2004. AMP-Activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem. Biophys. Res. Commun. 321:161-67
30. Bijland S, Mancini SJ, Salt IP. 2013. Role of AMP-Activated protein kinase in adipose tissue metabolism and inflammation. Clin. Sci. 124:491-507
31. Yu H, Pardoll D, Jove R. 2009. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9:798-809
32. Hirsch HA, Iliopoulos D, Struhl K. 2013. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc. Natl. Acad. Sci. USA 110:972-77
33. Ersoy C, Kiyici S, Budak F, et al. 2008. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res. Clin. Pract. 81:56-60
34. Rizos CV, Elisaf MS. 2013. Metformin and cancer. Eur. J. Pharmacol. 705:96-108
35. Iliopoulos D, Hirsch HA, Struhl K. 2011. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 71:3196-201
36. Dong L, Zhou Q, Zhang Z, et al. 2012. Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression. J. Obstet. Gynaecol. Res. 38:1077-85
37. EricesR, Bravo ML, Gonzalez P, et al. 2013. Metformin, at concentrations corresponding to the treatment of diabetes, potentiates the cytotoxic effects of carboplatin in cultures of ovarian cancer cells. Reprod. Sci. 20:1433-46
38. Asensio-LopezMC, LaxA, Pascual-Figal DA, et al. 2011. Metformin protects against doxorubicin-induced cardiotoxicity: involvement of the adiponectin cardiac system. Free Radic. Biol. Med. 51:1861-71
39. Chang J, Jung HH, Yang JY, et al. 2013. Protective effect of metformin against cisplatin-induced ototoxicity in an auditory cell line. J. Assoc. Res. Otolaryngol. 15:149-58
40. LandmanGW, Kleefstra N, vanHateren KJ, et al. 2010. Metformin associated with lower cancermortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33:322-26
41. Bowker SL, Yasui Y, Veugelers P, Johnson JA. 2010. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 53:1631-37
42. Currie CJ, Poole CD, Jenkins-Jones S, et al. 2012. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35:299-304
43. Franciosi M, Lucisano G, Lapice E, et al. 2013. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLOS ONE 8:e71583
44. Jiralerspong S, Palla SL, Giordano SH, et al. 2009. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J. Clin. Oncol. 27:3297-302
45. Bayraktar S, Hernadez-Aya LF, Lei X, et al. 2012. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 118:1202-11
46. Hou G, Zhang S, Zhang X, et al. 2013. Clinical pathological characteristics and prognostic analysis of 1, 013 breast cancer patients with diabetes. Breast Cancer Res. Treat. 137:807-16
47. Chen TM, Lin CC, Huang PT, Wen CF. 2011. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J. Gastroenterol. Hepatol. 26:858-65
48. Romero IL, McCormick A, McEwen KA, et al. 2012. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet. Gynecol. 119:61-67
49. Kumar S, Meuter A, Thapa P, et al. 2013. Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer 119:555-62
50. NevadunskyNS, Van Arsdale A, StricklerHD, et al. 2013. Metformin use and endometrial cancer survival. Gynecol. Oncol. 32:236-40
51. Garrett CR, Hassabo HM, Bhadkamkar NA, et al. 2012. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br. J. Cancer 106:1374-78
52. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D. 2012. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin. Cancer Res. 18:2905-12
53. SkinnerHD, McCurdyMR, Echeverria AE, et al. 2013. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol. 52:1002-9
54. Tan BX, Yao WX, Ge J, et al. 2011. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer 117:5103-11
55. Hadad S, Iwamoto T, Jordan L, et al. 2011. Evidence for biological effects ofmetformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res. Treat. 128:783-94
56. Niraula S, Dowling RJ, Ennis M, et al. 2012. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res. Treat. 135:821-30
57. Bonanni B, PuntoniM, CazzanigaM, et al. 2012. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J. Clin. Oncol. 30:2593-600
58. Hosono K, Endo H, Takahashi H, et al. 2010. Metformin suppresses colorectal aberrant crypt foci in a short-Term clinical trial. Cancer Prev. Res. 3:1077-83
59. Evans JM, Donnelly LA, Emslie-Smith AM, et al. 2005. Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304-5
60. Thakkar B, Aronis KN, Vamvini MT, et al. 2013. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-Analysis using primary data of published studies. Metab. Clin. Exp. 62:922-34
61. Zhang P, Li H, Tan X, et al. 2013. Association of metformin use with cancer incidence and mortality: a meta-Analysis. Cancer Epidemiol. 37:207-18
62. Home PD, Kahn SE, Jones NP, et al. 2010. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 53:1838-45
63. Janjetovic K, Vucicevic L, MisirkicM, et al. 2011. Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. Eur. J. Pharmacol. 651:41-50
64. Suissa S, Azoulay L. 2012. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35:2665-73
65. Azoulay L, Dell'Aniello S, Gagnon B, et al. 2011. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol. Biomark. Prev. 20:337-44
66. Smiechowski B, Azoulay L, Yin H, et al. 2013. The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus. Cancer Epidemiol. Biomark. Prev. 22:1877-83
67. Smiechowski BB, Azoulay L, Yin H, et al. 2013. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care 36:124-29
68. Mamtani R, Pfanzelter N, Haynes K, et al. 2014. Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. Diabetes Care 37:1910-17
69. National Cancer Institute. 2014. A phase III randomized trial of metformin versus placebo in early stage breast cancer. http://www.cancer.gov/clinicaltrials/search/view?cdrid=669788&version= HealthProfessional. Accessed Jan. 3, 2014
70. National Cancer Institute. 2014. Evaluation of metformin, targeting cancer stem cells for prevention of relapse in gynecologic patients. http://www.cancer.gov/clinicaltrials/search/view?cdrid=732286&version= HealthProfessional. Accessed Jan. 3, 2014
71. Brose MS, Rebbeck TR, Calzone KA, et al. 2002. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J. Natl. Cancer Inst. 94:1365-72
72. Higurashi T, Takahashi H, Endo H, et al. 2012. Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial. BMC Cancer 12:118